These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36930696)

  • 1. Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome.
    Murtada SI; Mikush N; Wang M; Ren P; Kawamura Y; Ramachandra AB; Li DS; Braddock DT; Tellides G; Gordon LB; Humphrey JD
    Elife; 2023 Mar; 12():. PubMed ID: 36930696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
    Suzuki M; Jeng LJB; Chefo S; Wang Y; Price D; Li X; Wang J; Li RJ; Ma L; Yang Y; Zhang X; Zheng N; Zhang K; Joseph DB; Shroff H; Doan J; Pacanowski M; Smpokou P; Donohue K; Joffe HV
    Genet Med; 2023 Feb; 25(2):100335. PubMed ID: 36507973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Shappell H; Massaro J; D'Agostino RB; Brazier J; Campbell SE; Kleinman ME; Kieran MW
    JAMA; 2018 Apr; 319(16):1687-1695. PubMed ID: 29710166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Kleinman ME; Massaro J; D'Agostino RB; Shappell H; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland RH; Nazarian A; Snyder BD; Ullrich NJ; Silvera VM; Liang MG; Quinn N; Miller DT; Huh SY; Dowton AA; Littlefield K; Greer MM; Kieran MW
    Circulation; 2016 Jul; 134(2):114-25. PubMed ID: 27400896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
    Cubria MB; Suarez S; Masoudi A; Oftadeh R; Kamalapathy P; DuBose A; Erdos MR; Cabral WA; Karim L; Collins FS; Snyder BD; Nazarian A
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12029-12040. PubMed ID: 32404427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
    Gordon LB; Massaro J; D'Agostino RB; Campbell SE; Brazier J; Brown WT; Kleinman ME; Kieran MW;
    Circulation; 2014 Jul; 130(1):27-34. PubMed ID: 24795390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.
    Gordon LB; Kleinman ME; Miller DT; Neuberg DS; Giobbie-Hurder A; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland R; Snyder BD; Fligor B; Bishop WR; Statkevich P; Regen A; Sonis A; Riley S; Ploski C; Correia A; Quinn N; Ullrich NJ; Nazarian A; Liang MG; Huh SY; Schwartzman A; Kieran MW
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16666-71. PubMed ID: 23012407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.
    Arnold R; Vehns E; Randl H; Djabali K
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
    Gordon CM; Cleveland RH; Baltrusaitis K; Massaro J; D'Agostino RB; Liang MG; Snyder B; Walters M; Li X; Braddock DT; Kleinman ME; Kieran MW; Gordon LB
    Bone; 2019 Aug; 125():103-111. PubMed ID: 31077852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hutchinson-Gilford Progeria paves the way for novel targeted anti-aging therapies.
    Dreesen O; Kennedy B
    Med; 2021 Apr; 2(4):353-354. PubMed ID: 35590156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment.
    Ullrich NJ; Kieran MW; Miller DT; Gordon LB; Cho YJ; Silvera VM; Giobbie-Hurder A; Neuberg D; Kleinman ME
    Neurology; 2013 Jul; 81(5):427-30. PubMed ID: 23897869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lonafarnib: First Approval.
    Dhillon S
    Drugs; 2021 Feb; 81(2):283-289. PubMed ID: 33590450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
    Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
    Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
    Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
    J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Qiao X; Fong LG; Young SG
    Biochim Biophys Acta; 2008; 1781(1-2):36-9. PubMed ID: 18082640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib.
    Gordon LB; Campbell SE; Massaro JM; D'Agostino RB; Kleinman ME; Kieran MW; Moses MA
    Pediatr Res; 2018 May; 83(5):982-992. PubMed ID: 29342131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progeria and the early aging in children: a case report.
    Carvalho VO; Celli A; Bancke Laverde BL; Cunico C; Santos Piedade G; Lucas de Mello M; Beirao Junior PS
    Dermatol Online J; 2016 Feb; 22(2):. PubMed ID: 27267192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome.
    Abutaleb NO; Atchison L; Choi L; Bedapudi A; Shores K; Gete Y; Cao K; Truskey GA
    Sci Rep; 2023 Mar; 13(1):5032. PubMed ID: 36977745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical aortic stiffening and subsequent cardiac dysfunction in Hutchinson-Gilford progeria syndrome.
    Murtada SI; Kawamura Y; Caulk AW; Ahmadzadeh H; Mikush N; Zimmerman K; Kavanagh D; Weiss D; Latorre M; Zhuang ZW; Shadel GS; Braddock DT; Humphrey JD
    J R Soc Interface; 2020 May; 17(166):20200066. PubMed ID: 32453981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.
    Kang SM; Yoon MH; Ahn J; Kim JE; Kim SY; Kang SY; Joo J; Park S; Cho JH; Woo TG; Oh AY; Chung KJ; An SY; Hwang TS; Lee SY; Kim JS; Ha NC; Song GY; Park BJ
    Commun Biol; 2021 Jan; 4(1):5. PubMed ID: 33398110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.